CD274 and gastric cancer: For example, the FDA has approved the detection of PD-L1 expression by immunohistochemistry as an accompanying diagnosis to guide the treatment of gastric cancer, urothelial carcinoma and NSCLC [36,37,38], but the standard detecting methods need to be unified.